Navigation Links
Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
Date:11/12/2010

s, plans and objectives of management are forward-looking statements.  The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to respond to the complete response letter regarding our new drug application for Linjeta™ in a timely manner and the possibility that information we provide in response to the letter may not be accepted by the FDA; our ability to secure FDA approval for Linjeta™ and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel™ technology; the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the FDA's findings regarding data anomalies observed in India in our Phase 3 clinical trial of Linjeta™ for patients with Type 1 diabetes; the possibility that patients taking Linjeta™ may experience more injection site discomfort than they experience with competing products; unexpected data that may result from our clinical trials and our research and development activities; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our
'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
2. Biodel Awarded $1.2 Million in Therapeutic Discovery Research Grants From IRS
3. FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta™
4. Biodel to Present at Upcoming Conferences
5. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
6. Biodel Appoints Arthur Urciuoli to its Board of Directors
7. Biodel to Raise $9.4 Million Through Registered Direct Offering
8. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
9. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
10. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
11. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... PARSIPPANY, N.J., July 7, 2011 Watson Pharmaceuticals, Inc. ... United States Court of Appeals for the Federal Circuit ... Southern District of Florida,s February 2011 decision that Watson,s ... Mucinex(R) DM (Dextromethorphan HBr/ Guaifenesin) Extended-Release products do not ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed an Abbreviated New Drug Application ... (FDA) seeking approval to market lisdexamfetamine dimesylate capsules. ... of Shire LLC,s Vyvanse®. Vyvanse® is a prescription ...
Cached Medicine Technology:Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit 2Watson Confirms Vyvanse® Patent Challenge 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... 2015 EBSCO Information Services (EBSCO) ... their relationship in an effort to further promote visibility and ... EBSCO has long made AMA journals available via its subscription ... The JAMA Network. , Long known as both ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... , WEDNESDAY, May 30 (HealthDay News) -- Nearly one in four ... be triggered by hot summer weather. Hives are itchy, red ... can be acute or chronic, according to the American Academy of ... than a day or up to six weeks, are likely a ...
... Breast-cancer researchers at the University of Wisconsin-Madison have found that ... together as a team to maintain normal activity in mammary ... breast cell types. They may also drive the development and ... Journal of Biological Chemistry , the research also suggests ...
... , , , , , , ... AUDIO: Smoking researchers at Washington University School of Medicine in Sr. Louis have found that the same genetic variations that ... for more information. , , , , ... , , , , , , , ...
... that can rapidly screen cells for leukemia or HIV ... can produce three-dimensional focusing of a stream of cells, ... counting CD4 cells," said Tony Jun Huang, associate professor ... of the diagnoses are done using flow cytometry." ...
... in one side of their visual field benefit from ... hearing sounds for an hour, their visual detection of ... field improved significantly. Neural pathways that simultaneously process information ... have embarked on a whole new therapy approach" says ...
... TUESDAY, May 29 (HealthDay News) -- Women who develop fevers ... have a child with autism spectrum disorder or another developmental ... if, fevers may increase the risk for autism is unknown, ... if they do develop a fever while pregnant because taking ...
Cached Medicine News:Health News:Summer's Heat May Enflame Hives 2Health News:Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved 2Health News:Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved 3Health News:Genes predict if medication can help you quit smoking 2Health News:Genes predict if medication can help you quit smoking 3Health News:Genes predict if medication can help you quit smoking 4Health News:Biochip-based device for cell analysis 2Health News:Biochip-based device for cell analysis 3Health News:Hear to see: New method for the treatment of visual field defects 2Health News:Fever During Pregnancy May Raise Odds for Autism in Offspring 2Health News:Fever During Pregnancy May Raise Odds for Autism in Offspring 3
... 14A and 14C have been approved. The three ... the variations in the size of the individual ... are designed to stabilize the capsule and have ... of U.S. ophthalmologists. For implatations of the ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Hannum rongeur/grasper with teth in jaws and non-locking design....
Medicine Products: